BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27267386)

  • 1. cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
    Bolger GB; Bizzi MF; Pinheiro SV; Trivellin G; Smoot L; Accavitti MA; Korbonits M; Ribeiro-Oliveira A
    Endocr Relat Cancer; 2016 May; 23(5):419-31. PubMed ID: 27267386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
    Bizzi MF; Pinheiro SVB; Bolger GB; Schweizer JROL; Giannetti AV; Dang MN; Ribeiro-Oliveira A; Korbonits M
    Mol Cell Endocrinol; 2018 Nov; 476():103-109. PubMed ID: 29729370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants.
    Hernández-Ramírez LC; Trivellin G; Stratakis CA
    Horm Metab Res; 2017 Apr; 49(4):286-295. PubMed ID: 28427099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
    Leontiou CA; Gueorguiev M; van der Spuy J; Quinton R; Lolli F; Hassan S; Chahal HS; Igreja SC; Jordan S; Rowe J; Stolbrink M; Christian HC; Wray J; Bishop-Bailey D; Berney DM; Wass JA; Popovic V; Ribeiro-Oliveira A; Gadelha MR; Monson JP; Akker SA; Davis JR; Clayton RN; Yoshimoto K; Iwata T; Matsuno A; Eguchi K; Musat M; Flanagan D; Peters G; Bolger GB; Chapple JP; Frohman LA; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2390-401. PubMed ID: 18381572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of the aip gene in familial pituitary tumorigenesis.
    Tahir A; Chahal HS; Korbonits M
    Prog Brain Res; 2010; 182():229-53. PubMed ID: 20541668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.
    Bolger GB; Peden AH; Steele MR; MacKenzie C; McEwan DG; Wallace DA; Huston E; Baillie GS; Houslay MD
    J Biol Chem; 2003 Aug; 278(35):33351-63. PubMed ID: 12810716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterases and cAMP Pathway in Pituitary Diseases.
    Bizzi MF; Bolger GB; Korbonits M; Ribeiro-Oliveira A
    Front Endocrinol (Lausanne); 2019; 10():141. PubMed ID: 30941100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.
    Mackenzie KF; Topping EC; Bugaj-Gaweda B; Deng C; Cheung YF; Olsen AE; Stockard CR; High Mitchell L; Baillie GS; Grizzle WE; De Vivo M; Houslay MD; Wang D; Bolger GB
    Biochem J; 2008 Apr; 411(2):361-9. PubMed ID: 18095939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaperones, somatotroph tumors and the cyclic AMP (cAMP)-dependent protein kinase (PKA) pathway.
    Schernthaner-Reiter MH; Trivellin G; Stratakis CA
    Mol Cell Endocrinol; 2020 Jan; 499():110607. PubMed ID: 31586652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIP gene and familial isolated pituitary adenomas.
    Ozfirat Z; Korbonits M
    Mol Cell Endocrinol; 2010 Sep; 326(1-2):71-9. PubMed ID: 20457215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
    Tuominen I; Heliövaara E; Raitila A; Rautiainen MR; Mehine M; Katainen R; Donner I; Aittomäki V; Lehtonen HJ; Ahlsten M; Kivipelto L; Schalin-Jäntti C; Arola J; Hautaniemi S; Karhu A
    Oncogene; 2015 Feb; 34(9):1174-84. PubMed ID: 24662816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
    Daly AF; Vanbellinghen JF; Khoo SK; Jaffrain-Rea ML; Naves LA; Guitelman MA; Murat A; Emy P; Gimenez-Roqueplo AP; Tamburrano G; Raverot G; Barlier A; De Herder W; Penfornis A; Ciccarelli E; Estour B; Lecomte P; Gatta B; Chabre O; Sabaté MI; Bertagna X; Garcia Basavilbaso N; Stalldecker G; Colao A; Ferolla P; Wémeau JL; Caron P; Sadoul JL; Oneto A; Archambeaud F; Calender A; Sinilnikova O; Montañana CF; Cavagnini F; Hana V; Solano A; Delettieres D; Luccio-Camelo DC; Basso A; Rohmer V; Brue T; Bours V; Teh BT; Beckers A
    J Clin Endocrinol Metab; 2007 May; 92(5):1891-6. PubMed ID: 17244780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of AIP with protein kinase A (cAMP-dependent protein kinase).
    Schernthaner-Reiter MH; Trivellin G; Stratakis CA
    Hum Mol Genet; 2018 Aug; 27(15):2604-2613. PubMed ID: 29726992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.
    Trivellin G; Butz H; Delhove J; Igreja S; Chahal HS; Zivkovic V; McKay T; Patócs A; Grossman AB; Korbonits M
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E708-19. PubMed ID: 22811466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition.
    Morgan RM; Hernández-Ramírez LC; Trivellin G; Zhou L; Roe SM; Korbonits M; Prodromou C
    PLoS One; 2012; 7(12):e53339. PubMed ID: 23300914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial pituitary adenomas - who should be tested for AIP mutations?
    Korbonits M; Storr H; Kumar AV
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):351-6. PubMed ID: 22612670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIP and its interacting partners.
    Trivellin G; Korbonits M
    J Endocrinol; 2011 Aug; 210(2):137-55. PubMed ID: 21454441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation.
    MacKenzie KF; Wallace DA; Hill EV; Anthony DF; Henderson DJ; Houslay DM; Arthur JS; Baillie GS; Houslay MD
    Biochem J; 2011 May; 435(3):755-69. PubMed ID: 21323643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.
    Cazabat L; Bouligand J; Salenave S; Bernier M; Gaillard S; Parker F; Young J; Guiochon-Mantel A; Chanson P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E663-70. PubMed ID: 22319033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics of pituitary adenomas.
    Gadelha MR; Trivellin G; Hernández Ramírez LC; Korbonits M
    Front Horm Res; 2013; 41():111-40. PubMed ID: 23652674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.